The Institute of Cancer Research, London, has strongly welcomed the approval by the European Commission of the targeted drug olaparib for men with advanced prostate cancers with genetic alterations in BRCA1 or BRCA2.

Aggressive cancers could be treated with immunotherapies that direct the immune system to kill cancer cells with specific drug resistance-causing mutations, a major new study suggests.

A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.